Harrow’s (HROW) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Harrow (NASDAQ:HROW) in a research report report published on Wednesday morning, Marketbeat.com reports. They currently have a $63.00 target price on the stock.

Other analysts have also issued reports about the company. William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Zacks Research lowered Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 3rd. HC Wainwright boosted their price objective on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Cantor Fitzgerald dropped their price objective on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Harrow has an average rating of “Moderate Buy” and an average price target of $71.14.

Harrow Trading Down 3.3%

Shares of HROW stock opened at $33.28 on Wednesday. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The firm has a market cap of $1.24 billion, a P/E ratio of -195.75 and a beta of 0.05. The company has a 50 day moving average of $44.53 and a 200-day moving average of $43.45. Harrow has a 12-month low of $20.85 and a 12-month high of $54.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Harrow by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock worth $94,162,000 after acquiring an additional 50,889 shares during the last quarter. Geode Capital Management LLC lifted its stake in Harrow by 4.7% in the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock worth $24,765,000 after purchasing an additional 36,724 shares during the last quarter. Marshall Wace LLP lifted its stake in Harrow by 31.5% in the second quarter. Marshall Wace LLP now owns 564,876 shares of the company’s stock worth $17,251,000 after purchasing an additional 135,202 shares during the last quarter. Penn Capital Management Company LLC boosted its position in Harrow by 20.5% during the fourth quarter. Penn Capital Management Company LLC now owns 392,067 shares of the company’s stock valued at $19,257,000 after buying an additional 66,589 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Harrow by 32.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 370,548 shares of the company’s stock valued at $18,159,000 after buying an additional 90,331 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.